

Fiona L.R. Williams*, Jennifer Watson, Chris Day, Aung Soe, Sateesh K. Somisetty, Lesley Jackson, Elena Velten^a and Anita Boelen

Thyroid dysfunction in preterm neonates exposed to iodine

DOI 10.1515/jpm-2016-0141

Received April 20, 2016. Accepted July 22, 2016. Previously published online August 26, 2016.

Abstract

Background: Infants <32 weeks' gestation should not be exposed to topical iodine and its avoidance is recommended during pregnancy and breast feeding. Exposure to contrast media and topical iodine is frequently used in many preterm neonates.

Aim: To determine whether thyrotropin levels in preterm infants are affected by exposure to intrapartum/neonatal topical iodine and/or the use of iodinated contrast media.

Design: Infants <32 weeks' gestation were recruited. Maternal and neonatal exposures to iodinated contrast media and topical iodine were recorded; levels of thyrotropin and thyroxine were measured from blood-spot cards on postnatal days 7, 14, 28 and the equivalent of 36 weeks' gestation.

Results: One hundred and twenty-five infants were exposed to topical iodine/contrast media and 48 infants were unexposed. No infants were treated for hypothyroidism; three infants (exposed group) had transient hyperthyrotropinaemia. Mean thyrotropin levels were significantly higher on postnatal days 7, 14 and 28 in infants exposed

to topical iodine prior to caesarean section compared to unexposed infants, a relationship which persisted after adjustment.

Conclusions: In the context of this study, neonatal thyroid dysfunction was seen following exposure to iodine via caesarean section but not via exposure to contrast media.

Keywords: Iodine; preterm; thyroid hormones; toxicity.

Introduction

The iodine requirement for healthy preterm infants is estimated, from balance studies, to be 30–40 µg/kg/day [1, 2]. Newborn infants receive iodine through three main sources: parenteral nutrition, enteral nutrition and breast milk. Most preterm infants are on parenteral nutrition initially and gradually change to enteral nutrition as their clinical condition improves. The current guideline for iodine intake in enteral nutrition for preterm infants is 11–55 µg/kg/day [3], whereas the current recommended iodine intake in parenteral nutrition regimens is 1 µg/kg/day [4]. The iodine content of breast milk reflects maternal iodine status, and a small study in Scotland reported mean levels to be ~10 µg/dL [5]. A review of several UK-manufactured formula brands (e.g. Comfort first infant formula, Cow & Gate Plus, Milupa Aptamil First, SMA Gold) found that none provided the recommended iodine intake of 90 µg/day at birth for term infants [6]. Parenteral nutrition and the iodine content of prescribed drugs and red blood cell concentrates together provided only 1–3 µg/iodine/day [5]. Neonates in the UK do not receive supplemental iodine as they are assumed to receive sufficient iodine from enteral and parenteral formulas and/or breast milk. This assumption is probably incorrect, especially for infants receiving parenteral nutrition [7].

In addition to the risk of iodine deficiency, paradoxically, preterm infants are also vulnerable to the effects of iodine overload because the Wolff-Chaikoff effect, which blocks the uptake of excess iodine by the thyroid gland, does not mature until around 36–40 weeks' gestation [8]. Neonatal overload may occur through the neonatal

^aMedical student.

*Corresponding author: **Fiona L.R. Williams**, PhD, Population Health Sciences, Ninewells Hospital and Medical School, Mackenzie Building, University of Dundee, Kirsty Semple Way, Dundee DD2 4BF, UK, Tel: +44 1382 383726, E-mail: f.l.r.williams@dundee.ac.uk

Jennifer Watson and Elena Velten: Population Health Sciences, School of Medicine, University of Dundee, Kirsty Semple Way, Dundee DD2 4BF, UK

Chris Day: Bradford Royal Infirmary, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford BD9 6RJ, UK

Aung Soe: Medway Maritime Hospital, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, UK

Sateesh K. Somisetty: Luton and Dunstable University Hospital NHS Foundation Trust, Lewsey Road, Luton LU4 0DZ, UK

Lesley Jackson: Southern General Hospital, 1345 Govan Road, Glasgow, Lanarkshire G51 4TF, UK

Anita Boelen: Neonatal Screening Laboratory, Laboratory of Endocrinology, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

use of iodinated contrast media [9] and/or iodinated skin disinfectants [10], if there is maternal exposure via supplements or topical iodine use during pregnancy or delivery, and there is additional infant exposure if the mother breastfeeds [11]. A major source of neonatal exposure is maternal exposure through the use of iodine-based skin disinfectants prior to caesarean section [12].

Several studies have confirmed neonatal thyroid dysfunction consequent to exposure to iodinated contrast media [13–15], but the results are inconsistent: one study found no evidence [16] of transient hypothyroidism and another, a rate of 75% [14]. The consequence of using iodine-based skin disinfectants is also variable, with rates of hypothyroidism reported from 0% [17, 18], 20% [19], 25% [10], to 78% [14].

Recent systematic reviews considered neonatal exposure to iodinated contrast media [20] and to topical iodine [21]. Both reviews concluded that the studies appraised were affected by bias but nevertheless, neonates exposed to iodinated contrast media and topical iodine appeared to be at risk of thyroid dysfunction and development of hypothyroidism. Preterm infants were identified at higher risk than term infants. Presumably in reflection of this inconsistent but scientifically rational evidence [22], the 2013–2014 edition of the British National Formulary (BNF) for Children [23] states that use of topical iodine is contraindicated in neonates <32 weeks' postmenstrual age and infants <1.5 kg, and regular use during pregnancy and while breastfeeding should be avoided. The equivalent American publication cautions that as iodine crosses the placenta, it may cause hypothyroidism/goitre in the foetus and the newborn [24]. There is no comment about iodinated contrast media as it is not a listed drug. However, guidance leaflets included with contrast media (e.g. Optiray 300-GB TL-05/2009) recommend monitoring thyroid function 6–10 days and 1 month after administration because of the risk of hypothyroidism due to iodine overload.

The aim of this study was to determine whether exposure to topical iodine or contrast media is associated with grossly altered thyroid function as reported by the earlier studies [14].

Methods

Infants <32 weeks' gestation were recruited between 2007 and 2012 from five neonatal intensive care units in the UK (two in Scotland and three in England); our aim was to recruit infants consecutively. The single exclusion criterion was serious congenital anomaly. Written informed consent was obtained from all mothers. The study was approved by the Medical Research Ethics Tayside Committee (A), 06/S1401/116.

This study compared infants categorised as either exposed or unexposed to topical iodine (maternal or neonatal use) and/or iodinated contrast media. Special care was taken by study nurses to record maternal exposure to iodine during pregnancy and parturition, dosage and type of neonatal exposure to contrast media, and the use of iodine-based skin disinfectants. Exposure was classified as (1) to neonatal contrast media only, (2) to topical iodine prior to caesarean section only, (3) mixed exposure and (4) unexposed. Exposure was confirmed by cross-checking obstetric and neonatal clinical records. Neonatal exposure data were collected prospectively by staff actively involved in the care of neonates and the study; obstetric data were collected retrospectively, but the majority of mothers delivered in the same hospital as the neonatal unit and obstetric policy regarding iodine use for skin disinfection is standard for all personnel in the unit.

The main outcome measures were levels of thyrotropin (TSH) and thyroxine (T4) measured on postnatal days 7, 14, 28 and at the equivalent of 36 weeks' gestation. Heel-prick blood was spotted onto filter-paper cards and posted immediately to the Neonatal Screening Laboratory, Academic Medical Centre, Amsterdam. The Dutch screening program for congenital hypothyroidism is primarily based on the T4 measurement in filter paper but measurements of TSH and thyroid binding globulin (TBG) are also performed. T4 levels are also expressed as a standard deviation (T4 sd) of the daily mean i.e. z score; levels ≤ -3.0 are considered abnormal. Assays were performed according to the manufacturer's protocol: total T4 by a fluoro immunoassay (AutoDelfia, Perkin Elmer, Waltham, MA, USA) and TSH by an immunometric assay (Brahms, Thermo scientific, Henningsdorf, Germany). Analysis of the blood-spot cards within the screening laboratory ensured that all suspect results were quickly notified to the neonatal unit and local diagnostic tests and treatment protocols instigated. We classified TSH levels ≥ 6 mU/L as the threshold of suspicion, as this is the lowest level of TSH to prompt recall for repeat testing used by a UK newborn screening laboratory for congenital hypothyroidism. Suspect levels were faxed to FLRW, who alerted the appropriate duty neonatal consultant. Hypothyroidism was classified if treatment with Levo-thyroxine was required; hyperthyrotropinaemia was classified as levels of TSH between 10.1 and 19.9 mU/L.

Clinical and demographic data were recorded from birth for 28 days, although a final blood sample was taken at the equivalent of 36 weeks' gestational age. Data recorded included gestation at birth, birth weight, birthweight ratio (infant weight standardised to national data), gender and on postnatal day 7, 14 and 28, type and quantity of nutrition, prescribed drug usage, neonatal illnesses/conditions and level of nursing care required (as a proxy of illness severity) [25].

Mean levels of TSH and T4 were calculated for infants grouped by source of iodine exposure for each day of blood sampling ($\pm a$ day). (Infants were only sampled once if their day-28 blood was within a day of their 36 weeks' blood.) Differences in mean levels between the exposed and unexposed groups were found using, as appropriate, the *t* test for unequal variance or Fisher's exact test. Univariate general linear models were used to evaluate TSH levels on days 7, 14 and 28 and the exposure group was adjusted for gestational age, level of nursing care required, birthweight ratio, gender, and drug usage. We collected information about the use of dexamethasone, dopamine and caffeine as these drugs can inhibit neonatal TSH secretion [26]. The target sample was 200 infants, which would give 80% power, $P=5\%$, to detect an incidence of hypothyroidism of 25% in the exposed group.

Results

Of the 173 infants in the study, 125 were exposed to extraneous iodine and 48 were unexposed (other than to dietary iodine contained in breast milk or added by manufacturers to formula milk). No infant was exposed to topical iodine for neonatal skin antiseptics; the most frequent exposure source was neonatal contrast media (Table 1).

Thirteen infants recorded a level of TSH ≥ 6 mU/L at one of the blood sampling days (Table 2); 6% (6/95) of infants exposed only to contrast media, 19% (3/16) of infants exposed only to maternal topical iodine and 8% (4/48) of the unexposed group (Tables 1 and 2). Overall, the incidence of thyroid dysfunction (TSH ≥ 6 mU/L) in our exposed cohort was 7.2% and 8.3% in the unexposed cohort. No infant was diagnosed with hypothyroidism; three infants had transient hyperthyrotropinaemia and all were from the exposed group. Five infants who had TSH ≥ 6 mU/L, all from the exposed group, had a T4 z score ≤ -3.0 ; the T4 levels in four infants normalised by the 36th week and one infant died.

Contrast media for verification of central venous catheter position was the most common source of iodine exposure (Table 1). Three types of media were used: Optiray 300, Omnipaque 240/250 and Ultravist 300. Doses ranged from 0.2 to 1.0 mL per application, with a mode of 0.3 mL. One hundred and eight infants were exposed to contrast media: Ultravist 300 was the most commonly used (52%), followed by Omnipaque 240 (32%), Optiray 300 (15%) and Omnipaque 250 (1%). Eighty-six infants received a single dose of media, 18 infants received two doses of media and four infants received three doses of media. The median days for receipt of the 1st, 2nd and 3rd doses of contrast media were, for the mixed exposure group, 3, 57 and 65 days post birth, while for the contrast-only exposure group, the medians were 3, 17 and 21 days, respectively. Twenty-one infants were exposed to topical iodine. The majority of infants received maternal breast milk during the first 28 days postnatal. Generally, breast

milk provided the majority of the nutritional intake (Table 3).

Compared to the unexposed infants, the infants exposed to iodine via caesarean section had significantly higher TSH and T4 levels on postnatal days 7, 14 and 28 (TSH only), although by the equivalent of 36 weeks' gestation, TSH and T4 levels between the groups did not differ (Table 4). Regression analyses confirmed the associations between TSH levels on days 7, 14 and 28 and iodine exposure from caesarean section, associations which persisted after adjustment for confounding factors (Table 5).

Compared to the unexposed infants, the mean gestational age at birth for the infants exposed only to contrast media and the mixed exposure group was significantly lower, and this is reflected by lower mean birthweights in these groups (Table 3). There were six neonatal deaths, three in the contrast media-only group and three in the unexposed group. There were no differences in the levels of illness experienced by the groups of infants (Supplementary Table 1). Neonatal dexamethasone and dopamine were used in $<1.5\%$ of infants: for the exposed group (1.1% and 1.3%, respectively) and the unexposed group (0.7% and 0%, respectively); caffeine (Table 3) was used for 69.3% of the exposed and 50.0% of the unexposed group.

The number of infants with missing neonatal blood data was low (range 0%–14%) for all exposure groups. By the 36th week, the amount of missing data was higher (range 20%–43%), particularly for the caesarean section-only and mixed exposure groups (Table 4). We did not monitor missed infants and estimate that we recruited 60% of eligible infants (Supplementary Table 2).

Discussion

This study aimed to determine whether the incidence of thyroid dysfunction following iodine exposure was as high as the 75%–78% previously reported [14]. We found

Table 1: Sources of neonatal exposure to iodine.

Sources of iodine exposure	
Single exposure source	
Neonatal contrast media	n=95
Topical iodine prior to caesarean section	n=16
Mixed exposure source	
Maternal use of vitamins containing iodine and neonatal contrast media	n=9
Topical iodine prior to caesarean section and neonatal contrast media	n=4
Neonatal use of iodine-based eye drops and possible maternal use of vitamins containing iodine	n=1
Unexposed	n=48

Table 2: Routes^a of extraneous iodine exposure, gestational age, postnatal TSH and T4 levels and date of death in infants who recorded TSH levels ≥ 6 mu/L.

Infant	Gestation (weeks+day)	Route and day of exposure	TSH mU/L day 7	T4 z score day 7	TSH mU/L day 14	T4 z score day 14	Route and day of exposure	TSH mU/L day 28	T4 z score day 28	TSH mU/L 36 weeks ^b	T4 z score 36 weeks ^b	Week of death if applicable
1	28+5	C/S	8	-2.1	3	-1.8		5	-2.4	4	-1.7	n/a
2	29+1	C/S	6	-1.4	7	-2.5		7	-1.4	Missing	Missing	n/a
3	28+6	C-M d3	10	-3.1	2	-2.1		11	-3.4	4	-2.9	n/a
4	31+2	C-M d6	9	-3.3	3	-1.9		4	-1.8	4	-1.3	n/a
5	30+1	C/S	2	-2.5	7	-2.1		2	-2.5	2	-1.8	n/a
6	24+6	C-M d3	1	-3.8	8	-2.7	C-M d17	1	-3.0	n/a	n/a	Equivalent of 32 weeks' gestation
7	27+4	C-M d3	1	-3.2	10	-2.4		5	-3.9	4	-1.7	n/a
8	28+0	C-M d2&3	1	-3.8	25	-3.2	C-M d20	1	-3.0	3	-2.4	n/a
9	29+5	C-M d0	3	-2.4	6	-2.8		Missing	Missing	Missing	Missing	n/a
Unexposed infants												
1	31+1		2	-1.2	8	-1.3		2	-1.9	2	0.4	n/a
2	28+0		2	-2.0	6	-1.9		2	-1.9	2	-1.2	n/a
3	30+2		4	-2.2	5	-2.5		6	-2.5	4	-1.3	n/a
4	31+1		1	-2.0	1	-2.3		6	-1.2	1	-1.6	n/a

C/S=caesarean section, C-M=contrast media for placement of central venous catheters.

^aNo infant was exposed to iodine for skin disinfectant prior to placement of long line or surgery.

^b36 weeks refers to the week of gestation that the preterm infant would have been in had they remained *in utero*.

an incidence of 7.2% of thyroid dysfunction (TSH ≥ 6 mU/L) in the exposed group and 8.3% for the unexposed group.

Quantitative information about the iodide content of contrast media is sparse. Iodinated contrast media contain variable but large amounts of bound iodide (biologically inactive), which liberate variable amounts of (biologically active) free iodide [16]. Manufacturers of contrast media do not specify the free and bound proportions of iodide used in their product sheets, and the amount of free iodide is likely to vary between and within manufacturers [14, 27]. A single dose of Omnipaque contrast media (with a small application of topical iodine for skin cleansing) was estimated to expose an infant to 243 $\mu\text{g}/\text{kg}$ of free iodide [14]. Another study reported a content range, for various media (including Omnipaque), of 2–21 $\mu\text{g}/\text{mL}$ [27]. Precise information about the actual dose of free iodide that an infant is exposed to is further confused by the *in vivo* degradation of iodide, which increases the biological load. The most commonly used contrast media in our cohort was Ultravist 300 at a modal dose of 0.3 mL, i.e. 90 mg of iodine. If we assume that 21 $\mu\text{g}/\text{mL}$ [27] is representative of the free iodide content of the contrast media used in our study, it suggests that our infants were exposed to about 6 $\mu\text{g}/\text{iodide}$ per dose, which could explain why so few of the infants showed a marked thyroid dysfunction.

Quantitative information about the free iodide content of topical iodine solutions is also not readily available. Furthermore, although the placenta can store iodine and perhaps protect the foetus from deficiency [28], it is not clear how infants become exposed to iodide from caesarean section and/or epidural anaesthesia. It could be via the blood directly, as iodide also crosses the placenta [22], but a more substantive source is likely to be breast milk, as iodide is actively concentrated in the breast [29].

Monitoring exposed infants will undoubtedly reveal high levels of urinary iodide [21], but increased levels do not establish definitive proof that the thyroid gland has been adversely affected. The assays measuring urinary iodine cannot distinguish between bound iodide and free iodide, and it is only the latter that is taken up by the thyroid gland [30]. Furthermore, comparatively few infants exposed to iodine, and with high levels of urinary iodide, actually exhibit thyroid dysfunction [15]. There are many other unknown facts. For instance, the relationship between urinary/serum iodide levels and thyroid function is unclear: infants exposed to the same quantities and types of contrast media show different thyroid responses and urinary iodide levels and exposure to contrast media and/or topical iodine can raise urinary iodine levels >1000-fold; yet, remarkably few exposed infants show thyroid dysfunction [15]. Because

Table 3: Infant and maternal characteristics.

	Exposed			Unexposed
	Caesarean section only n=16	Contrast media only n=95	Mixed exposure n=14	n=48
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
Gestation (weeks)	29.6 (1.5)	28.2 (1.9) ^a	27.1 (2.6) ^b	29.2 (2.0)
Birth weight (g)	1437 (329)	1154 (326) ^c	948 (262) ^d	1329 (333)
Birthweight ratio	1.1 (0.2)	1.0 (0.2)	0.9 (0.2)	1.0 (0.2)
Maternal thyroid disease				
Yes	0	7 (7%)	0	3 (6%)
No	16 (100%)	85 (90%)	13 (93%)	43 (90%)
Missing data	0	3 (3%)	1 (7%)	2 (4%)
Nutrition on day 7				
Breast milk (mL)	143 (92)	52 (59)	48 (98)	104 (99)
Formula milk (mL)	62 (79)	3 (18)	17 (43)	44 (77)
Total (mL)	216 (45)	170 (54)	160 (95)	198 (56)
Nutrition on day 14				
Breast milk (mL)	174 (133)	116 (93)	80 (78)	126 (112)
Formula milk (mL)	89 (121)	15 (44)	41 (82)	71 (102)
Total (mL)	263 (54)	185 (55)	147 (43)	216 (59)
Missing data		3		2
Nutrition on day 28				
Breast milk (mL)	127 (162)	176 (114)	91 (84)	129 (131)
Formula milk (mL)	198 (163)	34 (84)	74 (120)	133 (150)
Total (mL)	325 (73)	236 (70)	177 (65)	268 (78)
Missing data	2	7		10
Gender				
Female	7 (44%)	48 (51%)	5 (36%)	18 (38%)
Male	9 (56%)	47 (49%)	9 (64%)	30 (63%)
Caffeine day 7				
Yes	6 (38%) ^e	81 (85%)	11 (79%)	34 (71%)
No	10 (63%)	14 (15%)	3 (21%)	14 (29%)
Caffeine day 14				
Yes	3 (19%) ^f	83 (87%) ^g	12 (86%)	25 (52%)
No	13 (81%)	10 (11%)	2 (14%)	21 (44%)
Died	–	2 (2%)		2 (4%)
Caffeine day 28				
Yes	1 (6%)	55 (58%) ^h	8 (57%)	13 (27%)
No	15 (94%)	35 (37%)	6 (43%)	30 (63%)
Died	–	3 (3%)	–	3 (6%)
Missing data	–	2 (2%)	–	2 (4%)

^aCompared to unexposed $t=2.87$, $P=0.005$.

^bCompared to unexposed $t=2.79$, $P=0.013$.

^cCompared to unexposed $t=3.00$, $P=0.003$.

^dCompared to unexposed $t=4.49$, $P=0.0001$.

^eCompared to unexposed, Fisher exact $P=0.04$.

^fCompared to unexposed, Fisher exact $P=0.03$.

^gCompared to unexposed, Fisher exact $P=0.00002$.

^hCompared to unexposed, Fisher exact $P=0.002$.

of this ambiguity, we elected not to measure urinary/serum iodide levels in our exposed infants. We assumed that iodine exposure had occurred based on the circumstantial evidence provided by the previous research [13–15] and the cautionary notes of the contrast media manufacturers and BNF [23].

Our findings are generally quite different from those reported previously [9–11, 14, 19, 29] and from the conclusions drawn by systematic reviews of exposure via contrast media [20] and povidone-iodine [21]. How authors define and measure thyroid dysfunction may explain some of the disparity between studies. Many authors

Table 5: Regression analyses of exposure to iodine on TSH levels adjusted^a for confounding variables.

TSH level on day 7	Effect estimate	Standard error	t	P value
Iodine exposure group				
Caesarean section only	0.888	0.277	3.203	0.002
Mixed exposure	-0.042	0.312	-0.134	0.894
Contrast media only	-0.313	0.168	-1.859	0.065
Unexposed	Reference			
Nursing level of care				
Level 1 (highest level)	-0.314	0.212	-1.482	0.141
Levels 2 and 3 (moderate/low)	Reference			
Caffeine prescribed on day 7				
Yes	0.066	0.179	0.370	0.712
No	Reference			
Infant gender				
Male	-0.178	0.143	-1.250	0.213
Female	Reference			
Gestational age	-0.023	0.047	-0.485	0.628
Birth weight ratio	-1.265	0.418	-3.030	0.003
TSH level on day 14				
Iodine exposure group				
Caesarean section only	1.745	0.800	2.182	0.031
Mixed exposure	-1.360	0.874	-1.556	0.122
Contrast media only	-0.640	0.523	-1.224	0.223
Unexposed	Reference			
Nursing level of care				
Level 1 (highest level)	1.338	0.704	1.902	0.059
Level 2 and 3 (moderate/low)	Reference			
Caffeine prescribed on day 14				
Yes	0.845	0.567	1.491	0.138
No	Reference			
Infant gender				
Male	-0.029	0.403	-0.072	0.943
Female	Reference			
Gestational age	0.066	0.138	0.475	0.636
Birth weight ratio	-1.473	1.188	-1.240	0.217
TSH level on day 28				
Iodine exposure group				
Caesarean section only	1.282	0.365	3.509	0.001
Mixed exposure	-0.572	0.384	-1.490	0.139
Contrast media only	-0.252	0.231	-1.089	0.278
Unexposed	Reference			
Nursing level of care				
Level 1 (highest level)	-0.594	0.372	-1.596	0.113
Level 2 and 3 (moderate/low)	Reference			
Caffeine prescribed on day 28				
Yes	-0.330	0.237	-1.393	0.166
No	Reference			
Infant gender				
Male	0.007	0.186	0.040	0.968
Female	Reference			
Gestational age	-0.203	0.074	-2.722	0.007
Birth weight ratio	-1.839	0.557	-3.303	0.001

^aDexamethasone and dopamine usages were not used in the regression model as so few infants received these drugs.

Our study has an element of recruitment bias: although we aimed for consecutive recruitment, some infants were missed and our population was skewed to the older

gestations, which has the effect of attenuating any relationship between iodine exposure and neonatal thyroid outcome. We estimate that we might have missed 40%

of eligible infants, so even if all the missed infants had thyroid dysfunction, we would still report an incidence of well below the 78%–80% reported previously [14]. Our exposure source was biased towards contrast media, with relatively few infants exposed to topical iodine. While we collected information about drug usage that may affect levels of TSH and thyroid hormones, we did not collect any information about renal function, the impairment of which can affect clearance of iodine, which may, in turn, impact the risk of developing hypothyroidism.

The BNF cautions against the use of topical iodine in preterm infants and in women during pregnancy and breastfeeding, and manufacturers of contrast media recommend monitoring thyroid function after administration because of the risk of hypothyroidism due to iodine overload. The use of contrast media for neonates is widespread, and one study reported its use in 64% of UK neonatal units [34]. The use of topical iodine is not well recorded and its use in UK neonatal units has possibly decreased from around 21% in 2006 [21] to 1% in 2013 [35], as units move to chlorhexidine gluconate for skin antiseptics. Use of topical iodine in obstetric units is also poorly recorded, and one survey found that it was used in 57% of obstetric units [21]. However, obstetric and neonatal surgical applications of topical iodine are likely to be more harmful to the preterm infant than neonatal skin cleansing prior to catheter placements because the quantity of topical iodine used per application for skin cleansing prior to caesarean section or epidural or neonatal surgery is much greater than for neonatal catheter positioning.

From the results of this study, it is not possible to say unequivocally that exposure causes no harm, although the incidence of thyroid dysfunction as a result of exposure to iodinated contrast media is very unlikely to be near the high level reported by L'Allemand et al. [14]. But even with our perhaps over-strict definition of thyroid dysfunction, several infants in our study had transient thyroid dysfunction, which is associated with neurodevelopmental compromise [34]. The best evidence to date is from the systematic reviews which indicate that neonatal thyroid dysfunction is present in around 18%–20% of exposed infants [20, 21]. A randomised controlled trial is needed to determine unequivocally whether exposure to extraneous iodine causes thyroid dysfunction. In the meantime, clinicians can debate or act on the advice of the BNF [23], the American Pharmacists Association [24] and the manufacturers of contrast media. (Chlorhexidine or octenidine are alternatives to topical iodine, although it also holds risks for preterm infants [36]). However, until research is unequivocal, it is imperative that all preterm infants exposed to extraneous iodine have their thyroid function

monitored, for a sufficient period as per the manufacturers' advice, post exposure. Clinical guidelines, which define cut-offs for normal TSH and (F)T4 levels and which are relative to the gestational and postnatal age of the infant and the blood media used, are a priority.

Acknowledgements and Disclosures: Senior nursing staff at each of the hospitals supported the study by recruiting infants and recording clinical data; our thanks to: Alison O'Doherty, Bradford Royal Infirmary; Yvonne Millar and Jenny Baker, Luton & Dunstable University Hospital NHS Foundation Trust; Louise Proffitt and Simone Breugem Medway Maritime Hospital; Sharon Lynch, Princess Royal Maternity Unit, Glasgow; and Jill McFerran, Ninewells Hospital and Medical School, Dundee. Our thanks also to Marja van Veen-Sijne (Neonatal Screening Laboratory, Academic Medical Center, Amsterdam) for measuring T4 and TSH in heel prick samples.

Funding: Tenovus Scotland, Anonymous Trust, Dundee.

References

- [1] Delange F. Optimal iodine nutrition during pregnancy, lactation and the neonatal period. *Int J Endocrinol Metab.* 2004;2:1–12.
- [2] Ares S, Escobar-Morreale HF, Quero J, Presas MJ, Herruzo R, Morreale de Escobar G. Neonatal hypothyroxinaemia: effects of iodine intake and premature birth. *J Clin Endocrinol Metab.* 1997;82:1704–12.
- [3] Agostini C, Buonocore G, Carnielli VP, De Curtis M, Darmaun D, Decsi T, et al. Enteral nutrient supply for preterm infants: commentary from European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Committee on nutrition. *J Pediatr Gastroenterol Nutr.* 2010;50:85–91.
- [4] Greene HL, Hambidge KM, Schanler R, Tsang RC. Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorus in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition. *Am J Clin Nutr.* 1988;48:1324–42.
- [5] Ibrahim M, Morreale de Escobar G, Visser TJ, Durán S, van Toor H, Strachan J, et al. Iodine deficiency associated with parenteral nutrition in extreme preterm infants. *Arch Dis Child.* 2003;88:F56–7.
- [6] Hume R, Lang K, Williams FLR. Iodine content of standard formula and specialized enteral preparations. In: Preedy VR, Burrow GN, Watson RR, editors. *Comprehensive handbook of iodine: nutritional, biochemical, pathological and therapeutic aspects.* California, USA: Academic Press, Elsevier, Ch 41, 2009.
- [7] Zimmerman MB. Iodine: it's important in patients that require parenteral nutrition. *Gastroenterol.* 2009;137:S36–46.
- [8] Wolff J, Chaikoff IL. Plasma inorganic iodide as a homeostatic regulator of thyroid function. *J Biol Chem.* 1948;174:555–64.

- [9] Bühler UK, Girard J, Stalder G. Congenital iodide goitre and hypothyroidism due to intra-uterine application of iodine-containing contrast medium. *Acta Paediatr Scand.* 1973;62:108–9.
- [10] Smerdely P, Boyages SC, Wu D, Leslie G, John E, Lim A, et al. Topical iodine-containing antiseptics and neonatal hypothyroidism in very-low-birthweight infants. *Lancet.* 1989;2:661–4.
- [11] Carswell F, Kerr MM, Hutchinson JH. Congenital goitre and hypothyroidism produced by maternal ingestion of iodides. *Lancet.* 1970;1:1241–3.
- [12] Chan S, Hams G, Wiley V, Wilcken B, McElduff A. Postpartum maternal iodine status and the relationship to neonatal thyroid function. *Thyroid.* 2003;13:873–6.
- [13] Ares S, Pastor I, Quero J, Morreale de Escobar G. Thyroid complications including overt hypothyroidism related to the use of non-radiopaque silastic catheters for parenteral feeding in preterm infants requiring injection of small amounts of an iodinated contrast medium. *Acta Paediatr Scand.* 1995;84:579–84.
- [14] L'Allemand D, Grüters A, Beyer P, Weber B. Iodine in contrast agents and skin disinfectants is the major cause for hypothyroidism in infants during intensive care. *Horm Res.* 1987;28:42–9.
- [15] Parravicini E, Fontana C, Paterlini GL, Tagliabue P, Rovelli F, Leung K, et al. Iodine, thyroid function, and very low birth weight infants. *Pediatrics.* 1996;98:730–4.
- [16] Dembinski J, Arpe V, Kroll M, Hieronimi G, Bartmann P. Thyroid function in very low birth weight infants after intravenous administration of the iodinated contrast medium iopromide. *Arch Dis Child Fetal Neonatal Ed.* 2000;85:F215–7.
- [17] Brown RS, Bloomfield S, Bednarek FJ, Mitchell ML, Braverman LE. Routine skin cleansing with povidone-iodine is not a common cause of transient neonatal hypothyroidism in North America: a prospective controlled study. *Thyroid.* 1997;7:395–400.
- [18] Gordon CM, Rowitch DH, Mitchell ML, Kohane IS. Topical iodine and neonatal hypothyroidism. *Arch Pediatr Adolesc Med.* 1995;149:1336–9.
- [19] L'Allemand D, Grüters AJ, Heidemann P, Schürnbrand P. Iodine-induced alterations of thyroid function in newborn infants after prenatal and perinatal exposure to povidone iodine. *J Pediatr.* 1983;102:935–8.
- [20] Ahmet A, Lawson ML, Babyn P, Tricco AC. Hypothyroidism in neonates post-iodinated contrast media: a systematic review. *Acta Paediatr.* 2009;98:1568–74.
- [21] Aitken J, Williams FLR. A systematic review of thyroid dysfunction in preterm neonates exposed to topical iodine. *Arch Dis Child.* 2014;99:F21–8.
- [22] Roti E, Gnudi A, Braverman LE. The placental transport synthesis and metabolism of hormones and drugs which affect thyroid function. *Endocrinol Rev.* 1983;4:131–49.
- [23] British National Formulary for Children 2013–2014. London: BMJ Publishing Group Ltd, 2014.
- [24] American Pharmacists Association. Drug Information Handbook. 21st ed. Lexicomp, Ohio, USA: Lexicomp's drug reference handbooks, 2012. P. 1384–5.
- [25] Simpson J, Williams FLR, Delahunty C, van Toor H, Wu SY, Ogston SA, et al; Scottish Preterm Thyroid Group. Serum thyroid hormones in preterm infants and relationships to indices of severity of intercurrent illness. *J Clin Endocrinol Metab.* 2005;90:1271–9.
- [26] Williams FLR, Ogston SA, van Toor H, Visser TJ, Hume R; Scottish Preterm Thyroid Group. Serum thyroid hormones in preterm infants: associations with postnatal illnesses and drug usage. *J Clin Endocrinol Metab.* 2005;90:5954–63.
- [27] Laurie AJ, Lyon SG, Lasser EC. Contrast material iodides: potential effects on radioactive iodine thyroid uptake. *J Nucl Med.* 1992;33:237–8.
- [28] Burns R, Azizit F, Hedayati M, Mirmiran P, O'Herlihy C, Smyth PPA. Is placental iodine content related to dietary iodine intake? *Vlin Endocrin.* 2011;75:261–264.
- [29] Chanoine JP, Boulvain M, Bourdoux P, Pardou A, van Thi HV, Ermans AM, et al. Increased recall rate at screening for congenital hypothyroidism in breast fed infants born to iodine overloaded mothers. *Arch Dis Child.* 1988;63:1207–10.
- [30] Wiersinga WM. The effect of iodine-containing contrast media on the thyroid. *Eur J Hosp Pharma.* 2005;11:50–2.
- [31] Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet M, et al; on behalf of the ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE, the Congenital Hypothyroidism Consensus Conference Group. European Society for paediatric endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. *J Clin Endocrinol Metab.* 2014;99:363–84.
- [32] Williams FLR, Simpson J, Delahunty C, Ogston SA, Bongers-Schokking J, Murphy N, et al; Scottish Preterm Thyroid Group. Developmental trends in cord and postpartum serum thyroid hormones in preterm infants. *J Clin Endocrinol Metab.* 2004;89:5314–20.
- [33] De Zegher F, van den Bergher G, Dumoulin M, Gewillig M, Daenen W, Devlieger H. Dopamine suppresses thyroid-stimulating hormone secretion in neonatal hypothyroidism. *Acta Paediatr.* 1995;84:213–4.
- [34] Job S, Damodaran S, Brooke P, Mo J, Pickworth F, Clarke P. Incidence and identification of inadvertent lumbar vein catheterisation in the NICU. *Arch Dis Child Fetal Neonatal Ed.* 2015;100:F277–8.
- [35] ARCTIC Protocol. National perinatal epidemiology unit clinical trials unit. University of Oxford. 2015. Available at: www.npeu.ox.ac.uk/arctic. Table 1. P. 16. Accessed July 13th 2016.
- [36] Ponnusamy V, Venkatesh V, Clarke P. Skin antisepsis in the neonatae: what should we use? *Curr Opin Infect Dis.* 2014;27:244–50.

Supplemental Material: The online version of this article (DOI: 10.1515/jpm-2016-0141) offers supplementary material, available to authorized users.

The authors stated that there are no conflicts of interest regarding the publication of this article.